Stereotaxis Ord Stock Price, News & Analysis

Stereotaxis (NYSE: STXS) will participate in the Piper Sandler 37th Annual Healthcare Conference. David Fischel, chairman and CEO, will join a fireside discussion on December 3, 2025 at 9:00 AM ET and will be available for one-on-one investor meetings that day.

The release notes the company is achieving key regulatory milestones and showing early commercial growth. Stereotaxis develops robotic systems for minimally invasive endovascular intervention and reports its technology has been used to treat over 150,000 patients. The company included standard forward-looking risk disclosures about regulatory timing, market acceptance, and other business risks.

Stereotaxis (NYSE: STXS) reported results for the quarter ended September 30, 2025: total revenue $7.5M (Systems $1.9M; Recurring $5.6M). Gross margin was 55% (recurring 67%, systems 19%). Operating loss was $6.6M and net loss was $6.5M, with adjusted operating loss excl. non-cash charges of $2.5M. Negative free cash flow for Q3 was $4.2M. Cash on hand was $10.5M (pro forma $14.5M including an upcoming $4M financing tranche).

Operational highlights include FDA clearance for GenesisX, CE Mark and FDA submission for Synchrony, early commercial sales of MAGiC and MAGiC Sweep (>$300k revenue in first two months), and two Genesis orders in Europe. Company expects Q4 revenue >$9M and full-year 2025 revenue growth >20%.

Stereotaxis (NYSE: STXS) announced U.S. FDA 510(k) clearance for its new robotic system, GenesisX, on November 10, 2025. GenesisX preserves Robotic Magnetic Navigation while improving accessibility through built-in magnetic shielding, operation on standard 120/230V power, no structural anchoring, and an 80% smaller system cabinet, enabling installation in existing non-modified cath labs.

Stereotaxis has started a limited launch in the United States and Europe, is expanding compatible catheters and imaging compatibility, and is preparing supply chain, manufacturing, installation, and commercial processes for a full launch. GenesisX offers flexible capital models including sales, leases, and pay-per-use.

Stereotaxis (NYSE: STXS) will report its third quarter 2025 financial results on Tuesday, November 11, 2025 after the U.S. market close.

The company will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) the same day to discuss results and corporate developments. Participants may dial 800-715-9871 (US/Canada) or 646-307-1963 (international) using pass code 4402192. A live and replay webcast will be available via the company’s investor relations website, and a phone replay will be available for one month beginning about four hours after the call.

Stereotaxis (NYSE: STXS) announced on Oct 15, 2025 that it obtained CE Mark in Europe and submitted a 510(k) application to the FDA for the Synchrony system, a platform designed to modernize interventional cath labs. Synchrony pairs a 55" 4K display with <1 frame latency video digitization and is offered with SynX, a cloud app that the company says is HIPAA and GDPR compliant for remote connectivity, collaboration, recording, and monitoring. The company positions the platforms as foundational for future AI, remote procedures, and improved lab workflows.

Stereotaxis (NYSE: STXS) and CardioFocus announced a Collaboration Agreement on October 13, 2025 to advance a first‑ever robotic Pulsed Field Ablation (PFA) solution toward commercialization.

The collaboration pairs CardioFocus’ CE‑marked Centauri PFA system (used in >9,000 patients and reported in >40 publications) with Stereotaxis’ MAGiC catheter and Robotic Magnetic Navigation (RMN) platform (used in >150,000 patients and reported in >500 publications). Companies completed bench and pivotal preclinical studies showing safe, efficient, deep durable ventricular lesions and plan to move toward first‑human use, clinical trial initiation, regulatory compatibility work, and commercialization in the coming months.

Stereotaxis (NYSE:STXS), a pioneer in surgical robotics, announced that Erasmus Medical Center in Rotterdam has successfully performed its first procedures using the Genesis Robotic Magnetic Navigation System. Erasmus MC, having completed over 4,500 procedures with Stereotaxis technology, becomes the first center in The Netherlands to implement this advanced system.

The Genesis System represents the latest advancement in Robotic Magnetic Navigation technology, designed to treat arrhythmias through cardiac ablation. Dr. Sing-Chien Yap, Director of Electrophysiology at Erasmus Medical Center, highlighted the system's enhanced speed and responsiveness, particularly when combined with the MAGiC Catheter, benefiting patients with complex arrhythmias, including children and those with congenital heart disease.

Stereotaxis (NYSE: STXS) has achieved a significant milestone with the completion of the world's first procedures using MAGiC Sweep™, their pioneering robotically-navigated high-density electrophysiology mapping catheter. The procedures were successfully performed at Deborah Heart and Lung Center in New Jersey.

The MAGiC Sweep catheter demonstrated key advantages including accurate mapping of complex anatomy, stable cardiac tissue contact, clear electrogram signals, and absence of ventricular ectopy. Following recent FDA clearance, Stereotaxis has begun the commercial launch in the United States, while European regulatory clearance is pending.

This breakthrough represents a major advancement in robotic electrophysiology, with the technology already used to treat over 150,000 patients globally across the United States, Europe, and Asia.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has announced its participation in two upcoming investor conferences in New York City this September. CEO David Fischel will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10th, 2025, at 8:00 am EDT, and attend the Lake Street Capital 9th Annual Best Ideas Growth Conference on September 11th, 2025.

The company, which has treated over 150,000 patients globally with its robotic technology, will discuss its technological and commercial progress in its growth strategy. One-on-one meetings with Mr. Fischel can be arranged through conference registration.